The Fly | ACAD

First-in-Class PDP Treatment: NUPLAZID (pimavanserin) is the only FDA-approved medication specifically for Parkinson's Disease Psychosis, offering a unique therapeutic option for this patient population.

Unique MOA for NUPLAZID: Its selective serotonin inverse agonism at 5-HT2A receptors provides efficacy without the dopaminergic blockade that can exacerbate motor symptoms in Parkinson's patients, differentiating it from traditional antipsychotics.

Pioneering Rett Syndrome Therapy: DAYBUE (trofinetide) is the first and only FDA-approved treatment for Rett syndrome, addressing a critical unmet medical need in a rare disease population.

Clinical Trial Outcomes Risk: Failure of ongoing or future clinical trials could prevent new product approvals or expansion of existing indications, impacting future revenue and growth prospects.

Regulatory Approval Challenges Risk: Inability to obtain or maintain necessary regulatory approvals (e.g., from the FDA) for new products or new indications for existing products like NUPLAZID or DAYBUVUE could severely limit market access and sales potential.

Commercialization Success Risk: Challenges in successfully commercializing NUPLAZID and DAYBUVUE, including physician acceptance, patient adoption, and effective sales and marketing strategies, could hinder revenue growth and market penetration.

Pioneering Rett Syndrome Therapy: DAYBUE (trofinetide) is the first and only FDA-approved treatment for Rett syndrome, addressing a critical unmet medical need in a rare disease population.

Clinical Trial Outcomes Risk: Failure of ongoing or future clinical trials could prevent new product approvals or expansion of existing indications, impacting future revenue and growth prospects.